Drug
Lunsekimig
Lunsekimig: highest development phase Phase 2, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lunsekimig NCT06914908 | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps |
Latest
No recent events.
Follow Lunsekimig on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.